Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 300 of 494 entries
View as:

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00030966 Org: User:
Start: 01/31/02 End: 12/31/05 Due: 12/31/06

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT00559702 Org: User:
Start: 10/31/07 End: 11/30/11 Due: 11/30/12

A Study to Assess Choroideremia (CHM) Health Outcomes

Phase: N/A Priority: Normal
NCT ID: NCT04750785 Org: User:
Start: 12/15/20 End: 09/27/21 Due: 09/27/22

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT03283371 Org: User:
Start: 03/20/18 End: 11/18/20 Due: 11/18/21

Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012

Phase: N/A Priority: Normal
NCT ID: NCT01420458 Org: User:
Start: 08/31/11 End: 09/30/11 Due: 09/30/12

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

Phase: N/A Priority: Normal
NCT ID: NCT00871780 Org: User:
Start: 08/31/09 End: 07/31/12 Due: 07/31/13

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

Phase: N/A Priority: Normal
NCT ID: NCT01915901 Org: User:
Start: 08/31/13 End: 12/31/13 Due: 12/31/14

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074

Phase: N/A Priority: Normal
NCT ID: NCT02957617 Org: User:
Start: 02/10/17 End: 02/07/19 Due: 02/07/20

Single Ascending Doses of BIIB063 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02555085 Org: User:
Start: 09/30/15 End: 06/01/16 Due: 06/01/17

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00458861 Org: User:
Start: 03/31/07 End: 10/31/08 Due: 10/31/09

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Phase: N/A Priority: Normal
NCT ID: NCT02881567 Org: User:
Start: 04/18/17 End: 09/12/18 Due: 09/12/19

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT05265728 Org: User:
Start: 04/26/22 End: 05/27/24 Due: 05/27/25

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT06262477 Org: User:
Start: 01/02/24 End: 10/04/24 Due: 10/04/25

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

Phase: N/A Priority: Normal
NCT ID: NCT03507686 Org: User:
Start: 11/29/17 End: 06/29/22 Due: 06/29/23

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Phase: N/A Priority: Normal
NCT ID: NCT02052791 Org: User:
Start: 01/31/14 End: 01/31/17 Due: 01/31/18

Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency

Phase: N/A Priority: Normal
NCT ID: NCT00709865 Org: User:
Start: 07/31/08 End: 12/31/09 Due: 12/31/10

Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.

Phase: N/A Priority: Normal
NCT ID: NCT01978652 Org: User:
Start: 12/31/13 End: 02/28/14 Due: 02/28/15

Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany

Phase: N/A Priority: Normal
NCT ID: NCT02125604 Org: User:
Start: 06/30/14 End: 03/31/16 Due: 03/31/17

Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Phase: N/A Priority: Normal
NCT ID: NCT01181089 Org: User:
Start: 09/30/10 End: - Due: -

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Phase: N/A Priority: Normal
NCT ID: NCT04079088 Org: User:
Start: 06/30/21 End: 09/18/24 Due: 09/18/25

Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT05354414 Org: User:
Start: 05/11/22 End: 07/12/24 Due: 07/12/25

Brimonidine Tartrate for the Treatment of Injection Related Erythema

Phase: N/A Priority: Normal
NCT ID: NCT02568111 Org: User:
Start: 02/29/16 End: 08/31/16 Due: 08/31/17

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04924140 Org: User:
Start: 06/30/21 End: 10/01/21 Due: 10/01/22

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Phase: N/A Priority: Normal
NCT ID: NCT02142205 Org: User:
Start: 05/31/12 End: 12/31/13 Due: 12/31/14

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00575068 Org: User:
Start: 01/31/02 End: 11/30/10 Due: 11/30/11